Kenneth W. Narducy
President chez St. Charles Pharmaceuticals
Profil
Kenneth W.
Narducy is currently the Chief Operating Officer & Director at NeuroNascent, Inc. and the President at St. Charles Pharmaceuticals.
Previously, he held positions such as Chairman at Colby Pharmaceutical Co. from 2006 to 2013, Manager-Research & Development at Abbott Laboratories, Vice President-Research & Development at Wesley Jessen VisionCare, Inc., Vice President & General Manager at Centaur Pharmaceuticals, Inc., President & Executive Vice President at Oculex Pharmaceuticals, Inc., and Vice President-Research & Development at CooperVision Pharmaceuticals, Inc. Dr. Narducy holds an MBA degree from The University of Chicago and a doctorate degree from The Ohio State University.
Postes actifs de Kenneth W. Narducy
Sociétés | Poste | Début |
---|---|---|
St. Charles Pharmaceuticals | President | 17/09/2009 |
NeuroNascent, Inc.
NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | Directeur des opérations | - |
Anciens postes connus de Kenneth W. Narducy
Sociétés | Poste | Fin |
---|---|---|
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Président | 01/01/2013 |
ABBOTT LABORATORIES | Directeur Technique/Scientifique/R&D | - |
Wesley Jessen VisionCare, Inc. | Directeur Technique/Scientifique/R&D | - |
CooperVision Pharmaceuticals, Inc. | Directeur Technique/Scientifique/R&D | - |
Oculex Pharmaceuticals, Inc.
Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | President | - |
Formation de Kenneth W. Narducy
The University of Chicago | Masters Business Admin |
The Ohio State University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ABBOTT LABORATORIES | Health Technology |
Entreprise privées | 7 |
---|---|
Wesley Jessen VisionCare, Inc. | Health Technology |
Centaur Pharmaceuticals, Inc. | Health Technology |
NeuroNascent, Inc.
NeuroNascent, Inc. Pharmaceuticals: MajorHealth Technology NeuroNascent, Inc. is an IND-enabling stage biopharmaceutical company that develops orally available, novel therapeutics aimed at halting or reversing chronic neurological disorders. It offers disease-modifying therapeutics for some of the most difficult to treat brain disorders that include Alzheimer's disease, Parkinson's disease, and Down syndrome. The Company is founded by Judith Kelleher-Andersson in May 2004 and is headquartered in Clarksville, MD. | Health Technology |
Oculex Pharmaceuticals, Inc.
Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Health Technology |
St. Charles Pharmaceuticals | |
CooperVision Pharmaceuticals, Inc. | |
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |